Since 40-60% of sporadic meningiomas have a loss of NF2 expression, meningiomas can be molecularly categorized into NF2 mutants and non-NF2 mutants, with the latter predominantly comprised of TRAF7, KLF4, AKT1, SMO, and P13K mutations (17, 18). This evidence concerns the gene NF2 and meningioma.